{"url_path":"/sec/anvs/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1477845/0001104659-26-062626-index.html","accession_number":"0001104659-26-062626","cik":"0001477845","ticker":"ANVS","issuer_name":"Annovis Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1477845/0001104659-26-062626-index.html","primary_entity_key":"0001477845","primary_entity_name":"Annovis Bio, Inc."},"word_count":765,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n​\n\n**Exhibit**\n**Number**\n\n  ​ ​ ​\n\n**Description of Exhibit**\n\n \n\n3.1\n\n[Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit 3.1 to Form 8-K filed February 6, 2020.)](https://www.sec.gov/Archives/edgar/data/1477845/000110465920011925/tm206971d1_ex3-1.htm)\n\n \n\n3.2\n\n[Amended and Restated Bylaws of the Registrant. (Incorporated by reference to Exhibit 3.2 to Form 8-K filed February 6, 2020.)](https://www.sec.gov/Archives/edgar/data/1477845/000110465920011925/tm206971d1_ex3-2.htm)\n\n​\n\n​\n\n​\n\n3.3\n\n​\n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed June 16, 2023.)](https://www.sec.gov/Archives/edgar/data/1477845/000110465923072250/tm2318997d1_ex3-1.htm)\n\n​\n\n​\n\n​\n\n4.1\n\n​\n\n[Specimen Certificate evidencing shares of the Registrant’s common stock. (Incorporated by reference to Exhibit 4.1 to Amendment No. 3 to the Registration Statement on Form S-1 filed September 20, 2019.)](https://www.sec.gov/Archives/edgar/data/1477845/000104746919005362/a2239691zex-4_1.htm)\n\n​\n\n​\n\n​\n\n4.2\n\n​\n\n[Form of Warrant Agreement (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on November 1, 2023.)](https://www.sec.gov/Archives/edgar/data/1477845/000110465923113281/tm2329368d4_ex10-1.htm)\n\n​\n\n​\n\n​\n\n4.3\n\n​\n\n[Form of Warrant (Incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on February 5, 2025)](https://www.sec.gov/Archives/edgar/data/1477845/000110465925009279/tm255497d1_ex4-1.htm)\n\n​\n\n​\n\n​\n\n4.4\n\n​\n\n[Warrant Agency Agreement (Incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed on February 5, 2025)](https://www.sec.gov/Archives/edgar/data/1477845/000110465925009279/tm255497d1_ex4-2.htm)\n\n​\n\n​\n\n​\n\n10.1+\n\n​\n\n[Second Amended and Restated Employment Agreement dated as of March 24, 2020 between the Registrant and Maria Maccecchini (Incorporated by reference to Exhibit 10.1 to Form 10-K filed March 25, 2020.)](https://www.sec.gov/Archives/edgar/data/1477845/000110465920038326/tm2013055d1_ex10-1.htm)\n\n​\n\n​\n\n​\n\n10.2+\n\n​\n\n[Annovis Bio, Inc. 2018 Equity Incentive Plan. (Incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-8 filed February 14, 2020.)](https://www.sec.gov/Archives/edgar/data/1477845/000104746919003982/a2239177zex-10_2.htm)\n\n​\n\n​\n\n​\n\n10.3+\n\n​\n\n[Amendment to Annovis Bio, Inc. 2019 Equity Incentive Plan (Incorporate by reference to form DEF 14A filed April 29, 2024.)](https://www.sec.gov/Archives/edgar/data/1477845/000110465924054167/tm243000d1_def14a.htm)\n\n​\n\n​\n\n​\n\n10.4\n\n​\n\n[Registration Rights Agreement dated as of December 19, 2014 among the Registrant and the signatories thereto. (Incorporated by reference to Exhibit 10.5 to Amendment No. 1 to Form S-1 filed August 8, 2019.)](https://www.sec.gov/Archives/edgar/data/1477845/000104746919004651/a2239387zex-10_5.htm)\n\n​\n\n​\n\n​\n\n10.5+\n\n​\n\n[Form of Non-Qualified Stock Option Award Agreement for the Annovis Bio, Inc. 2019 Equity Incentive Plan. (Incorporated by reference to Exhibit 10.6 to the Annual Report on Form 10-K filed on March 31, 2023)](https://www.sec.gov/Archives/edgar/data/1477845/000110465923040275/anvs-20221231xex10d6.htm)\n\n​\n\n​\n\n​\n\n10.6\n\n​\n\n[Distribution Agreement, dated December 11, 2024, by and between Annovis Bio, Inc. and Oppenheimer & Co. Inc. (Incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed December 12, 2024)](https://www.sec.gov/Archives/edgar/data/1477845/000110465924127439/tm2430444d2_ex1-1.htm)\n\n​\n\n​\n\n​\n\n10.7\n\n​\n\n[Underwriting Agreement, dated February 3, 2025, by and between Annovis Bio, Inc. and ThinkEquity LLC (Incorporated by reference to Exhibit 1.1 to the Current Report filed on February 5, 2025)](https://www.sec.gov/Archives/edgar/data/1477845/000110465925009279/tm255497d1_ex1-1.htm)\n\n​\n\n​\n\n​\n\n19.1\n\n​\n\n[Insider Trading Policy (Incorporated by reference to Exhibit 19.1 to the Annual Report on Form 10-K filed on March 21, 2025).](https://www.sec.gov/Archives/edgar/data/1477845/000155837025003482/anvs-20241231xex19d1.htm)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n32\n\n[Table of Contents](#TOC)\n\n31.1*\n\n[Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](anvs-20260331xex31d1.htm)\n\n \n\n32.1**\n\n[Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](anvs-20260331xex32d1.htm)\n\n​\n\n​\n\n101.INS*\n\n​\n\nXBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n​\n\n​\n\n​\n\n101.SCH*\n\n​\n\nInline XBRL Taxonomy Extension Schema Document\n\n​\n\n​\n\n​\n\n101.CAL*\n\n​\n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n​\n\n​\n\n​\n\n101.DEF*\n\n​\n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n​\n\n​\n\n​\n\n101.LAB*\n\n​\n\nInline XBRL Taxonomy Extension Labels Linkbase Document\n\n​\n\n​\n\n​\n\n101.PRE*\n\n​\n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n​\n\n​\n\n​\n\n104*\n\n​\n\nCover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n*Filed herewith\n\n** Furnished herewith\n\n​\n\n​\n\n​\n\n​\n\n​\n\n33\n\n[Table of Contents](#TOC)\n\nSIGNATURES\n\n​\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n​\n\n**Annovis Bio, Inc.**\n\n​\n\n**Signature**\n\n  ​ ​ ​\n\n**Title**\n\n  ​ ​ ​\n\n**Date**\n\n \n\n \n\n \n\n/s/ Maria Maccecchini\n\n​\n\nPresident and Chief Executive Officer (Principal\n\n​\n\nMay 15, 2026\n\nMaria Maccecchini\n\n​\n\nExecutive and Principal Financial Officer)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n34"}